Telomere length as a prognostic parameter in CLL

Telomere length as a prognostic parameter in CLL

VJHemOnc

1 year
75 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Telomere erosion and fusion play an important role in the pathology of many common human malignancies, including chronic lymphocytic leukemia (CLL). In this interview, Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff University, Cardiff, UK, discusses the findings of a study analyzed the telomere profiles of CLL patients, to give a better idea of the replicative history of the disease. The study identified the shortest telomeres ever recorded in primary human tissue, reinforcing the concept that there is significant cell division in CLL. The study also provided evidence that critical telomere shortening, dysfunction and fusion contribute to disease progression. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.
Up Next Autoplay
Phase III Lumoxiti #ASH19
Phase III Lumoxiti #ASH19
Category: Chronic Lymphocytic Leukemia
40 Views
ash 3 weeks
Sickle Cell Research #ASH19
Sickle Cell Research #ASH19
Category: Chronic Lymphocytic Leukemia
2 Views
ash 3 weeks
Transcend CLL 004 Update #ASH19 @cityofhope
Transcend CLL 004 Update #ASH19 @cityofhope
Category: Chronic Lymphocytic Leukemia
7 Views
ash 4 weeks
Phase III ELEVATE TN Trial #ASH19 #ASH @TheUSONetwork
Phase III ELEVATE TN Trial #ASH19 #ASH @TheUSONetwork
Category: Chronic Lymphocytic Leukemia
14 Views
ash 4 weeks
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
Category: Chronic Lymphocytic Leukemia
23 Views
Cancer-News 4 weeks
MURANO Trial #ASH19 @abbvie
MURANO Trial #ASH19 @abbvie
Category: Chronic Lymphocytic Leukemia
50 Views
ash 1 month
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
20 Views
ash 1 month
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
5 Views
ash 1 month
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
3 Views
ash 1 month
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
22 Views
ash 1 month